EGFR is overexpressed in many types of cancers, and activates various downstream signalling pathways including the Phosphoinositide 3-kinase/Akt pathway [23], which activates SREBP1 cleavage and up-regulates SCD1, acetyl-coa carboxylase (ACC), and fatty acid synthase (FASN), leading to enhanced lipid metabolism [13, 22]. Here, SCD is linked to cancer.